Sign up for a free trial and join thousands of other leading professionals. Click here to start!

Acute Coronary Syndrome News

Home | Index > Health > Heart & Blood > Acute Coronary Syndrome

TAKE THIS POLL
Is Belgian Prime Minister Herman Van Rompuy the right person to lead the EU as its president? (Nov. 20, 2009) Yes. No. Don't know.

Sort by: relevance (24 hours) relevance date

Acute coronary syndromes and myocardial infarction 24 Nov 2009 14:55 GMT
... Royal Society of Medicine, 1 Wimpole St, London W1G 0AE This meeting, supported by the London ...
Do Drug Ads Make Meds More Expensive? 24 Nov 2009 22:51 GMT
... Plavix was initially approved in 1997 for prevention of cardiovascular events and treatment of acute coronary syndromes. Direct-to-consumer advertising began in 2001 by its U.S. marketers, Bristol-Myers Squibb and sanofi-aventis. The ...
AstraZeneca Files NDA for Acute Coronary Syndrome Drug 20 Nov 2009 06:58 GMT
... AstraZeneca Files NDA for Acute Coronary Syndrome Drug AstraZeneca is seeking FDA approval for its Brilinta treatment to reduce heart attacks ...
Nanosphere Submits 510(k) for Acute Coronary Syndromes Assay 19 Nov 2009 00:33 GMT
... Nanosphere Submits 510(k) for Acute Coronary Syndromes Assay Nanosphere, Inc. … announced it submitted a 510(k) application to the FDA for ...
Results From Two Phase II Trials Add To Understanding Of Ticagrelor (BRILINTA™) And How It Works In The Body 19 Nov 2009 13:21 GMT
... p-values for this difference at the >30% and >50% IPA levels were both "In acute coronary syndromes, a rapid and sustained antiplatelet effect is desirable since patients are at highest risk ...

Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics 19 Nov 2009 07:16 GMT
... trial, which was designed to evaluate the safety and biological activity of VT-111 in Acute Coronary Syndrome (ACS) patients receiving coronary stents. "The positive safety and efficacy data from this trial ...
Low Bleeding Rates Observed in Dabigitran Dose-Ranging Trial 19 Nov 2009 16:15 GMT
... patients who were already being treated with aspirin and clopidogrel (Plavix), researchers said here. "Acute coronary syndrome patients continue to have recurrent ischemic events despite evidence based treatment, including dual antiplatelet ...
Low Bleeding Rates Observed in Dabigatran Dose-Ranging Trial 19 Nov 2009 20:10 GMT
... patients who were already being treated with aspirin and clopidogrel (Plavix), researchers said here. "Acute coronary syndrome patients continue to have recurrent ischemic events despite evidence based treatment, including dual antiplatelet ...
Results From Two Phase II Trials Add To Understanding Of Ticagrelor (BRILINTA(TM)) And How It Works In The Body 19 Nov 2009 11:31 GMT
... called coronary heart disease, is most often caused by atherosclerosis, and can lead to acute coronary syndrome (ACS). Ticagrelor (BRILINTA(TM)) is an investigational oral antiplatelet treatment for acute coronary syndromes (ACS) ...
Newer Blood Thinners May Outperform Old Standbys 20 Nov 2009 04:32 GMT
... States) proved to be safe in preventing blood clots when patients were treated for acute coronary syndrome, a cluster of symptoms that might indicate a heart attack. "Dabigatran seems to be ...

Not satisfied with this news section? Make your own with the Newsletter Manager or try our other media monitoring services.

AstraZeneca Submits US New Drug Application for Ticagrelor (BRILINTA(TM)), an Investigational Antiplatelet Agent 19 Nov 2009 07:50 GMT
... oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS). The proposed trade name for ticagrelor is BRILINTA(TM), pending approval from the FDA. ...
AstraZeneca Submits US New Drug Application for Ticagrelor (BRILINTA(TM)), an Investigational Antipl 19 Nov 2009 07:56 GMT
... oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS). The proposed trade name for ticagrelor is BRILINTA(TM), pending approval from the FDA. ...
AstraZeneca Submits US New Drug Application for Ticagrelor (Brilinta), an Investigational Antiplatelet Agent 19 Nov 2009 13:31 GMT
... oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS). The proposed trade name for ticagrelor is BRILINTA(TM), pending approval from the FDA. ...
AstraZeneca Submits US New Drug Application for Brilinta (Ticagrelor), an Investigational Antiplatelet Agent 20 Nov 2009 11:11 GMT
... oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS). The proposed trade name for ticagrelor is BRILINTA, pending approval from the FDA. ...
BioMed News Bytes: AstraZeneca, Delcath, Unilife 20 Nov 2009 14:33 GMT
... oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS). The proposed trade name for ticagrelor is BRILINTA, pending approval from the FDA. ...
New Drug Application for ticagrelor submitted to the FDA 23 Nov 2009 11:53 GMT
... oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS). The proposed trade name for ticagrelor is BRILINTA(TM), pending approval from the FDA. ...
New Drug Application for ticagrelor submitted to FDA 19 Nov 2009 09:28 GMT
... oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS). The proposed trade name for ticagrelor is BRILINTA(TM), pending approval from the FDA. ...
AstraZeneca (AZN) Submits US New Drug Application for Ticagrelor (BRILINTA(TM)) 19 Nov 2009 11:34 GMT
... oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome ( ). The proposed trade name for ticagrelor is BRILINTA(TM), pending approval from the ...
AstraZeneca submitts NDA for Brilinta 19 Nov 2009 14:51 GMT
... oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS). The proposed trade name for ticagrelor is BRILINTA, pending approval from the FDA. ...
Does Simplicity Compromise Accuracy in ACS Risk Prediction? A Retrospective Analysis of the TIMI and GRACE Risk Scores 21 Nov 2009 09:35 GMT
... infarction (STEMI) and the Global Registry of Acute Coronary Events (GRACE) risk scores for in-hospital and ... tools for assessing risk in Acute Coronary Syndrome (ACS) patients. The objective of our study ...

THESE STORIES ARE NOT PUBLISHED BY IPD GROUP, INC. AND THESE LINKS WILL TAKE YOU TO OTHER WEBSITES. SOME OF THESE WEBSITES REQUIRE THEIR OWN REGISTRATION TO READ THEIR STORIES. PLEASE READ THE DISCLAIMER FOR MORE DETAILS. >>>

Positive results from chronic stu... 20 Nov 2009 13:10 GMT
... disorders, including VTE treatment, stroke prevention in patients with atrial fibrillation, secondary prevention of acute coronary syndrome, and VTE prevention in hospitalized, medically ill patients. To learn more about thrombosis, please ...
Positive Results From Chronic Study With Bayer's Rivaroxaban Will Be Presented As A Late Breaker At ASH 2009 21 Nov 2009 09:33 GMT
... range of acute and chronic blood-clotting disorders, including VTE treatment, , secondary prevention of acute coronary syndrome, and VTE prevention in hospitalized, medically ill patients. The Bayer Group is a global ...
Positive Results from Chronic Study with Bayer 's Rivaroxaban Will be Presented As a Late Breaker at ASH 2009 19 Nov 2009 19:59 GMT
... disorders, including VTE treatment, stroke prevention in patients with atrial fibrillation, secondary prevention of acute coronary syndrome, and VTE prevention in hospitalized, medically ill patients. To learn more about thrombosis, please ...
Positive Results from Chronic Study with Bayer ?s Rivaroxaban Will be Presented As a Late Breaker at ASH 2009 19 Nov 2009 22:50 GMT
... disorders, including VTE treatment, stroke prevention in patients with atrial fibrillation, secondary prevention of acute coronary syndrome, and VTE prevention in hospitalized, medically ill patients. To learn more about thrombosis, please ...
AstraZeneca Submits US New Drug Application for Ticagrelor (BRILINTA(TM)), an Investigational Antiplatelet Agent (PRN) 19 Nov 2009 07:54 GMT
... the Phase III head-to-head trial comparing ticagrelor plus aspirin with clopidogrel (Plavix®) plus aspirin. Acute coronary syndrome (ACS) is an umbrella term for conditions that result from a reduction in blood ...